Taiyu Investment

Name

Taiyu Investment

Legal name

Taiyu Investment (泰煜投资)

Website

https://tigeryeah.com/

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

akta.pro secondary industry

Corporate Finance & Capital Advisory (BPAHADAB)

Keywords

• Healthcare venture capital
• Medical device investment
• Early-stage biotech funding
• Innovative drug investment
• Healthcare fund management

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Distribution channels1 record

Marketing channels2 records

Core offering

Taiyu Investment is a healthcare-focused venture capital firm that manages seven RMB-denominated funds with over 20 billion RMB in total assets under management, primarily investing in early and growth-stage companies developing innovative medical devices, novel drugs, biotechnology, medical services, and nutrition health products. The firm also provides post-investment services including clinical and registration consulting, industry resource connections, and follow-on financing support to accelerate portfolio companies' commercialization. Since its 2014 founding, the firm has invested in more than 140-150 projects, with over 80% of investments placed at angel, Pre-A, and A round stages.

Product overview

Taiyu Investment is a venture capital firm (泰煜投资) that operates as a fund management platform rather than a traditional product company. Its core offering consists of investment fund management services across seven RMB funds, with over 20 billion RMB in assets under management. The company provides post-investment services to portfolio companies including clinical and registration consulting, financing support, and industry resource matching. The investment focus spans innovative medical devices, novel drugs, biotechnology, medical services, and nutrition health sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare Venture Capital Fund Management Management of seven RMB-denominated venture capital funds focused on early and growth-stage healthcare companies with strong innovation potential and core intellectual property, deploying over 20 billion RMB in total assets under management. The firm invests in innovative medical devices, novel drugs, biotechnology, medical services, and nutrition health, with over 80% of investments at angel, Pre-A, and A round stages.
• Post-Investment Support Services Comprehensive post-investment services for portfolio companies including connecting them with upstream and downstream industry customers, providing clinical and registration consulting to accelerate product market entry, and facilitating follow-on financing rounds. These services leverage the Tigermed CRO platform and the team's industry network.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Tigermed (泰格医药)coreStrategic or Co-development Partner · 1 January 2014Tigermed is the controlling shareholder and core investment platform of Taiyu Investment. This relationship provides access to clinical trial resources, regulatory expertise, industry network, and post-investment support capabilities for portfolio companies.

Scale indicators4 records

Recent moves14 records

Expansion highlights5 records

Broad incumbents

• CICC Capital (中金资本): Investment arm of China International Capital Corporation with diversified PE/VC funds including healthcare exposure. Comparable Chinese institutional investor profile but with broader mandate.
• CDH Investments (鼎晖投资): One of China's largest alternative asset managers with broad sector exposure including a sizable healthcare practice. Comparable as a major Chinese LP-style investor in healthcare but less specialized than Taiyu.
• Hillhouse Capital (高瓴资本): Asia-focused investment manager with a notable healthcare/biotech franchise. Comparable Chinese AUM scale but with broader sector mandate than Taiyu's healthcare-only focus.
• Sequoia Capital China (红杉中国): Major Chinese VC with broad sector coverage including a substantial healthcare practice. Comparable as a large-scale Chinese VC but healthcare is one of several verticals, not a sole focus like Taiyu.

Direct peers

• OrbiMed Advisors: Global healthcare-dedicated investment firm active across venture, growth, and public stages. Recurring co-investor with Taiyu (e.g., Zhitai Biotech Series C) and directly comparable on healthcare-only investment mandate.
• Qiming Venture Partners (启明创投): Leading Chinese VC with one of the largest healthcare practices, frequently co-investing alongside Taiyu (e.g., Zhitai Biotech Series C). Directly comparable on healthcare investment mandate and early-stage Chinese focus.
• Legend Capital (君联资本): Chinese PE/VC firm with a dedicated healthcare team investing across innovative drugs, devices, and diagnostics. Comparable stage range and sector focus to Taiyu.
• Highlight Capital (弘晖资本): China-focused healthcare VC firm investing in medical devices, biopharma, and digital health across early and growth stages. Closest comparable to Taiyu given similar sector focus, stage profile, and Chinese AUM scale.
• Lake Bleu Capital (清池资本): Hong Kong-based healthcare-focused public and private investment manager with deep China exposure. Comparable to Taiyu in healthcare sector specialization and Chinese biopharma/medical-device deal flow.
• Lilly Asia Ventures (礼来亚洲基金): Asia-focused healthcare VC with significant China presence investing in innovative drugs, devices, and diagnostics. Comparable as a healthcare-only specialist VC operating across similar early-stage rounds in China.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments48 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taiyu Investment